23-04-2012 15:56 A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones. Once these cells are guided to the bone surface by this molecule, the stem cells differentiate into bone-forming cells and synthesize proteins to enhance bone growth. The study, which was published online today in Nature Medicine, used a mouse model of osteoporosis to demonstrate a unique treatment approach that increases bone density and prevents bone loss associated with aging and estrogen deficiency. "There are many stem cells, even in elderly people, but they do not readily migrate to bone," said Wei Yao, the principal investigator and lead author of the study. "Finding a molecule that attaches to stem cells and guides them to the targets we need is a real breakthrough." Researchers are exploring stem cells as possible treatments for a wide variety of conditions and injuries, ranging from peripheral artery disease and macular degeneration to blood disorders, skin wounds and diseased organs. Directing stem cells to travel and adhere to the surface of bone for bone … Continue reading →

PHILADELPHIA Perelman School of Medicine researchers Thomas Curran, PhD, professor of Pathology and Laboratory Medicine, and Gary A. Koretzky, MD, PhD, vice chair for research and chief scientific officer, Department of Medicine, and are among the 220 elected to the 2012 class of members of the American Academy of Arts and Sciences. One of the nation's most prestigious honorary societies, the Academy is also a leading center for independent policy research. The current membership includes some of the world's most accomplished leaders from academia, business, public affairs, the humanities and the arts. Gary A. Koretzky is also a Francis C. Wood professor in the Department of Medicine. Through investigations of the regulation of blood cell formation and movement, Koretzky has made inroads into understanding the complexities of immune system function. Thomas Curran is also an investigator at the Abramson Family Cancer Research Institute and deputy scientific director at the Children's Hospital of Philadelphia. Curran's studies of the molecular basis of brain cell growth have informed new strategies to treat pediatric brain tumors. He is an elected member of the Institute of Medicine and of the Royal Society. The other Penn winners admitted to this years' class are Robert M. Seyfarth, … Continue reading →

BOLOGNA, Italy--(BUSINESS WIRE)-- Silicon Biosystems, S.p.A., a provider of specialized molecular and cellular biology technologies, will present at the Fourth World Circulating Tumour Cells Summit, April 25, 2012 at 3:30 p.m. at the Maritim Hotel in Berlin. Dr. Nicol Manaresi, founder and chief technology officer of Silicon Biosystems, will provide an overview of the DEPArray system, which uses image-based single-cell sorting to deliver pure populations of rare tumor cells. As part of the presentation, Dr. Manaresi will also offer recent data demonstrating single-CTC molecular characterization based on Whole Genome Amplification using the companys proprietary Ampli1 WGA kit followed by sequencing with Ion Torrent. Silicon Biosystems is a device manufacturer leading the field in the detection and isolation of single cells for cancer research and prenatal genetic testing. The companys DEPArray technology exploits microelectronics and the principles of dielectrophoresis to find, sort, isolate, and collect 100 percent pure populations of rare cells, such as CTCs, for single-cell based genomic and transcriptional profiling. The collection of pure individual CTCs from biological samples is a game changer in the quest to obtain clinical utility of these cells as it enables individual cell-based molecular profiling for personalized therapy, going beyond existing cell counting approaches … Continue reading →

Public release date: 25-Apr-2012 [ | E-mail | Share ] Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System The University of Michigan's second human embryonic stem cell line has just been placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research. It is the second of the stem cell lines derived at U-M to be placed on the registry. The line, known as UM11-1PGD, was derived from a cluster of about 30 cells removed from a donated five-day-old embryo roughly the size of the period at the end of this sentence. That embryo was created for reproductive purposes, tested and found to be affected with a genetic disorder, deemed not suitable for implantation, and would therefore have otherwise been discarded when it was donated in 2011. It carries the gene defect responsible for Charcot-Marie-Tooth disease, a hereditary neurological disorder characterized by a slowly progressive degeneration of the muscles in the foot, lower leg and hand. CMT, as it is known, is one of the most common inherited neurological disorders, affecting one in 2,500 people in the United States. People with CMT usually begin to experience symptoms in adolescence or early adulthood. The … Continue reading →